Application YC di Exin Therapeutics

Winter 2025Active

Exin Therapeutics ha partecipato a Y Combinator nel batch Winter 2025 come azienda Healthcare. Sotto: cosa fa l'azienda, chi l'ha fondata e la sua application a YC, ricostruita domanda per domanda nel form reale di YC.

Batch YC: Winter 2025
Settore: HealthcareTherapeutics
Dimensione team: 9
Stato: Active
Lanciata: 2025

Founder

Gabriel Ocana SanteroFounder
Marko TvrdicFounder

Cosa fa Exin Therapeutics

We use AI and high-throughput mouse studies to discover therapeutics that modify neural activity in the brain. The initial focus is on epilepsies associated with autism and Parkinson’s disease with the potential to expand to any neurological disorder underlined by a dysfunction in neural activity. Our R&D is guided by AI models trained on high-density multimodal mouse data generated in-house. We are 3 Oxford-trained neuroscientists supported by an experienced SAB from Harvard, Science Corp (ex-Neuralink), EPFL, Meta, and UCL. In 1.5 months since landing in SF, we went from nothing to (1) opening and operating an animal lab in South SF, (2) obtaining a proof-of-concept in mice, (3) building a multimodal AI model that directs our screening approach and (4) submitting two provisional patents; all while utilizing less than 50% of our YC funding.

Application YC di Exin Therapeutics, ricostruita

Domanda per Y Combinator

Exin Therapeutics, batch Winter 2025. Le vere domande del form, risposte da dati pubblici.

Founders2
Company7
Progress7
Idea4
Equity3
Curious2
Batch Preference1

Company

Company name

Exin Therapeutics

Describe what your company does in 50 characters or less.

AI drug discovery platform for neurotherapeutics

What is your company going to make? Please describe your product and what it does or will do.

We are building an AI-driven platform that analyzes high-density multimodal mouse data to discover drugs that modify neural activity. Initially, we target epilepsies associated with autism and Parkinson's disease, but our approach could extend to other neurological disorders involving dysfunctional neural activity.

Where do you live now, and where would the company be based after YC?

We live in San Francisco, CA, and the company is based here post-YC.

Explain your decision regarding location.

We are in San Francisco to be close to biotech investors, collaborators, and research talent. Setting up an animal lab here allows fast iteration between AI insights and in vivo validation, which is key for our approach.

21 risposte in più nell'application completa

Founders, Progress, Idea, Equity, Curious, Batch Preference sono nella versione completa. Crea un account gratuito per aprirla in YC Insights, accanto a ogni altro batch YC.

Vedi domanda completa

Domande Frequenti

Questa è l'application YC reale di Exin Therapeutics?

No. Y Combinator mantiene private le application inviate. Questa è una ricostruzione: le domande del form YC reale, a cui si è risposto usando i dati pubblici di Exin Therapeutics (note di lancio, background dei founder, descrizione del prodotto). Mostra come un'azienda come Exin Therapeutics si presenterebbe a YC, non il testo che hanno inviato.

A quale batch YC apparteneva Exin Therapeutics?

Exin Therapeutics apparteneva al batch Winter 2025 di Y Combinator.

Chi ha fondato Exin Therapeutics?

Exin Therapeutics è stato fondato da Gabriel Ocana Santero, Marko Tvrdic.

Cosa fa Exin Therapeutics?

AI drug discovery platform for neurotherapeutics

Come leggo la ricostruzione completa della application?

Crea un account Round Funded gratuito. La versione completa di 26 risposte della application di Exin Therapeutics, e di ogni altro batch YC, è in YC Insights.